EGFR lung cancer mutants get specialized

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 38, 2013, Pages 15169-15170

  Littlefield, Peter ^a   Jura, Natalia ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE INHIBITOR; SIGNAL PEPTIDE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME STRUCTURE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; NOTE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84884297381     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314719110     Document Type: Note

References (14)

1. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500.
2. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139.
3. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36): 13306-13311.
4. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73.
5. Red Brewer M, et al. (2013) Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc Natl Acad Sci USA 110:E3595-E3604.
6. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125(6):1137-1149.
7. Yun CH, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3):217-227.
8. Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277(48): 46265-46272.
9. Choi SH, Mendrola JM, Lemmon MA (2007) EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 26(11):1567-1576.
10. Zhang X, et al. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450(7170): 741-744.
11. Gajiwala KS, et al. (2013) Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 21(2): 209-219.
12. Shan Y, et al. (2012) Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149(4):860-870.
13. Macdonald-Obermann JL, Piwnica-Worms D, Pike LJ (2012) Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging. Proc Natl Acad Sci USA 109(1):137-142.
14. Olayioye MA, et al. (1998) ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 18(9):5042-5051.